Paloma Partners Management Co Acquires New Position in Corvus Pharmaceuticals Inc (CRVS)

Paloma Partners Management Co acquired a new position in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,900 shares of the company’s stock, valued at approximately $58,000. Paloma Partners Management Co owned about 0.05% of Corvus Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Trexquant Investment LP purchased a new stake in shares of Corvus Pharmaceuticals in the third quarter worth approximately $107,000. Rhumbline Advisers increased its position in shares of Corvus Pharmaceuticals by 44.1% during the fourth quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock valued at $67,000 after acquiring an additional 5,570 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter valued at approximately $182,000. Prudential Financial Inc. increased its position in shares of Corvus Pharmaceuticals by 15.0% during the fourth quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock valued at $79,000 after acquiring an additional 2,805 shares during the last quarter. Finally, Credit Suisse AG purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter valued at approximately $194,000. 85.71% of the stock is owned by hedge funds and other institutional investors.

Shares of CRVS opened at $4.00 on Tuesday. Corvus Pharmaceuticals Inc has a 12 month low of $3.22 and a 12 month high of $13.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.10. On average, research analysts predict that Corvus Pharmaceuticals Inc will post -1.66 earnings per share for the current fiscal year.

CRVS has been the subject of a number of research analyst reports. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Monday, January 14th. ValuEngine downgraded Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Wedbush decreased their price target on Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a research report on Wednesday, March 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $11.94.

TRADEMARK VIOLATION NOTICE: This piece was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://sportsperspectives.com/2019/04/02/paloma-partners-management-co-acquires-new-position-in-corvus-pharmaceuticals-inc-crvs.html.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Read More: QQQ ETF

Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals Inc (NASDAQ:CRVS).

Institutional Ownership by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.